Compare Franklin FTSE South Korea ETF (FLKR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin FTSE South Korea ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Franklin FTSE South Korea ETF trades at $49.48 (market cap $1.67B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Franklin FTSE South Korea ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Franklin FTSE South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FLKR | MRVI | |
|---|---|---|
Market Cap | $1.67B | $972.90M |
Volume | 703,703 | 4,325,710 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $9.00 |
52-Week Low | $28.48 | $2.83 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLKR (Franklin FTSE South Korea ETF) is trading at $54.89, down 2.03% with a bearish technical signal (16 sell vs 6 buy signals). The ETF faces pressure from semiconductor sector volatility and rising global yields, though some analysts see current levels as a potential buying opportunity. Technical indicators show strong resistance at $55-$56 with support at $53-$54 levels. The fund remains heavily concentrated in Korean memory chip giants Samsung and SK Hynix, making it highly sensitive to AI and semiconductor cycles.
While FLKR faces near-term headwinds from semiconductor volatility and macroeconomic pressures, long-term prospects remain tied to AI-driven demand for Korean tech. The current discount to growth expectations presents opportunity, but investors must weigh concentration risk against potential semiconductor recovery. Key risks include political tensions, currency fluctuations, and global interest rate environment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Franklin FTSE South Korea ETF
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
